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suggesting a similar overall survival benefit for the two drugs.
Furthermore survival subset analyses in BR21 were consistent
with ISEL, with the largest survival benefits for erlotinib also seen
in the never-smoking and Asian subgroups. The objective
response rates were comparable for gefitinib and erlotinib in
these two studies (8% vs. 9%, respectively).1,2
As the ISEL result was surprising, a number of comparisons
have been made.3
In ISEL 45% of patients had progressed and only 18%
responded on the most recent chemotherapy, whereas for BR21
28% progressed and 38% had responded, the more refractory
patients may have had less chance of benefiting. Erlotinib has a
greater affinity for the receptor and was used at the MTD
(150 mg) the similar dose for gefitinib would be 700 mg not the
250 mg used in ISEL. Further work investigating patient character-
istics e.g. smoking status, identification of more sensitive popula-
tions and molecular markers will be important.
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S54. PROTEIN LYSATE ARRAY ASSESSMENT OF THERAPEUTIC
TARGETS IN SARCOMA
Dennis P.M. Hughes. Children’s Cancer Hospital at M. D. Anderson
Cancer Center, TX, USA.
Small molecule inhibitors have brought new hope for cancers
with dire prognoses. These molecular medicines turn off specific
signaling intermediaries within cells, leaving others unaffected.
Their efficacy has been demonstrated clinically with medicines
such as imatinib for CML and GI stromal tumor and erlotinib for
EGFR-dependent head and neck, lung and breast cancer. More
small molecules are being developed. To rationally apply this
development to more diseases, a rapid screening tool is required
to identify expression and activity of protein targets in an individ-
ual patient’s tumor. The technical challenges for this tool are sig-
nificant: assessing dozens, if not hundreds, of potential targets
accurately using the small amount of tissue available through
core needle biopsies. We have begun applying a novel technology
– protein lysate array analysis – to address this problem in sar-
coma. Tumor lysates are arrayed on nitrocellulose matrix using
a modified DNA arrayer, creating 100+ duplicate slides using as
little as one microgram total protein. Individual slides are assayed
with monospecific antibodies and comparisons made between
phospho- and total protein levels, identifying the activation state
of dozens of potential therapeutic targets. We have used this
technique preclinically to test the downstream effects of erlotinib
in osteosarcoma and Ewing sarcoma, identifying changes in
MAPK, mTOR, AKT and JNK pathway signaling. We will use it in
a clinical trial of an anti-ERBB medicine to assess the correlation
between disease response and changes in signaling, using paired
samples of pre- and post-treatment tissue. We envision prospec-
tive testing of tumor tissue, allowing the clinician to choose those
small molecule(s) able to inhibit the specific pathway(s) active in
an individual’s tumor.
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S55. MOLECULAR STAGING OF NSCLC: 2006
Thomas J. Lynch Jr. Massachusetts General Hospital Cancer Center,
Boston, MA, USA.
The treatment of lung cancer has undergone a remarkable trans-
formation over the past five years. Previously histology and ana-
tomic stage were the primary determinants of treatment. While
these still have an important role, the future of treating this dis-
ease will be based on molecular staging strategies. This will allow
us to select more effective and less toxic treatments in the initial
treatment of metastatic disease. It will also permit informed
selection of patients for adjuvant treatment. Finally aggressive
molecular staging will hopefully uncover new targets that will
result in new drugs that may one day transform lung cancer into
a chronic disease with long-term survival the rule and not the
exception.
Agents that target the epidermal growth factor receptor (EGFR)
tyrosine kinase are among the most important new drugs in use
to treat non-small cell lung cancer. Both gefitinib and erlotinib are
capable of producing remarkable tumor responses as single
agents that are durable. These dramatic responses are often asso-
ciated with mutations in the EGFR tyrosine kinase domain. In
addition when used in second and third line treatment of lung
cancer erlotinib has been shown to prolong survival in this set-
ting. This clinical benefit is best predicted by increased EGFR gene
copy number as measured by FISH.
The use of EGFR-TKI provides an exceptional opportunity for
molecular staging. EGFR mutation testing is being used to select
patients for first line treatment with both gefitinib and erlotinib.
Trials in the United States, Japan and Europe are employing this
strategy and early results should be reported by the end of 2006.
The potential to identify a population of patients who might be
able to be treated with EGFR-TKI monotherapy as first line would
potentially deliver equivalent anti-tumor activity with fewer side
effects than combination chemotherapy.
Measurement of gene copy number by FISH is being used to
select patients for treatment with EGFR-TKI treatment in several
clinical scenarios. Patients who are FISH positive are being
entered onto trials of erlotinib plus chemotherapy as first line
treatment. Adjuvant studies of chemotherapy plus erlotinib given
as sequential therapy are under review. Finally there is some con-
troversy as to the relative value of EGFR protein expression as
measured by immunoperoxidase staining. Some thoughtful
investigators feel that the best way to select adjuvant and first
line metastatic patients for TKI treatment is by using a combina-
tion of FISH and immunoperoxidase staining.
While FISH and immunoperoxidase may be important modal-
ities in the molecular staging of lung cancer, mutation testing
offers a potential benefit not available with those methods.
Patients who are resistant to EGFR-TKI treatment have been found
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to harbor secondary mutations in EGFR which may predict both
primary and secondary resistance. The best studied of these is
the T790M mutation which is seen in nearly half of patients with
acquired resistance to drug. Furthermore mutation testing allows
clinicians to base treatment based on the type of mutation. It is
highly likely that not all mutations will be equivalent in predicting
response. Deletions in exon 19 are likely to be more predictive of
response to TKI treatment than point mutations in exon 21. Fur-
thermore there is emerging evidence that mutations in exon 20
might be predictive of primary resistance to EGFR treatment.
Selection of agents based on mutation testing is under review
in the setting of secondary resistance to EGFR-TKI treatment. A
phase II study of dual kinase, irreversible inhibitor HKI-272 is
underway in North America and Europe. In this trial patients
who have progressed after 12 weeks of TKI treatment are treated
with HKI-272 in cohorts based on mutation status. It is highly
likely that several new agents in development will be entered into
similarly designed studies.
EGFR is not the only target where molecular staging will be of
use. Ras is an important target in lung cancer, particularly smo-
ker’s lung cancer. Mutations in K-ras are seen in nearly 30% of
NSCLC patients. While the Ras farnesyl transferase inhibitors
have not proven to be of clinical benefit there are several other
agents that have preclinical activity and will be examined in
patients with ras-mutations. Determination of ras-mutation sta-
tus has been proposed by some to be helpful in predicting resis-
tance to EGFR-TKI so this might have even more relevance in
lung cancer treatment.
Finally gene expression arrays are under intensive investiga-
tion as potentially useful molecular staging tests. Studies are
underway to determine the utility of expression profiling as a
means of determining prognosis in lung cancer. While this tech-
nique is currently limited to fresh tissue if it proves useful it may
become a routine test performed on resected lung cancers to help
prognosticate outcome and to select patients for potential adju-
vant trials.
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S56. siRNA-TECHNOLOGY ON THE ROAD TO MOLECULAR
THERAPY
Steven Dooley, Patrico Godoy. Center of Molecular Alcohol Research
in Gastroenterology, II. Medical Clinic, University Hospital Mannheim,
University of Heidelberg, Germany.
The possibility to specifically knock down gene expression in a
cellular system is a powerful way to study its function. RNA inter-
ference (RNAi) as molecular mechanism for gene silencing in
mammalian cells has allowed the discovery of several new and
exciting regulatory mechanisms in apoptosis, cell cycle and can-
cer. The technology was recently improved by new delivery meth-
ods allowing both enhanced and long lasting silencing of target
genes, that is, more efficient transfection reagents, and genera-
tion of plasmid and virus based vectors for siRNA delivery. The
possibility of RNAi-scale up for high-throughput (HT) analyses
was used in several genome-wide screens. Thus, HT knock down
for mammalian kinases revealed important new features in the
control of critical cellular steps of endocytosis. The power of these
approaches can be harnessed to delineate complex signal trans-
duction pathways leading to disease. TGF-b is a major cytokine
in liver physiology. It regulates both cell proliferation and apopto-
sis of hepatocytes, and is the main drive of fibrosis, a typical com-
plication of chronic liver diseases. Our goals are to use high
throughput siRNA technologies to discover new and pathobio-
chemically relevant regulatory components of the TGF-b pathway
in liver cells with potential as targets for therapeutic intervention.
doi:10.1016/j.ejcsup.2006.04.058
S57. INTEGRATION SITE MONITORING IN CLINICAL GENE
THERAPY
Christof von Kalle. National Center of Tumor Diseases (NCT)
Heidelberg, Germany.
Retroviral gene therapy has been coming of age, reaching unprec-
edented levels of therapeutic efficacy. While the monoallelic inte-
gration of replication-defective vectors was thought to be without
considerable consequences on the host genome, recent reports
on vector integration related genotoxicity in preclinical animal
models have raised concerns on the biosafety of clinically applied
vectors. Possible side effects of vector integration ranged from
immortalization of transduced cells, clonal dominance to inser-
tional oncogenesis. A vector related genotoxicity has occurred
in leukemogenesis in 3 SCID-X1 patients, with remarkable consis-
tency by vector-induced LMO2 oncogene activation, putatively
enhanced by a synergetic effect of the constitutively expressed
vector transgene IL2RG. In the first successful gene therapy trial
of chronic granulomatous disease, we have now observed even
more intensive but thus far non-toxic insertional side effects
resulting in activation of MDS1/EVI1, PRDM16 or SETBP1 5 months
after therapy that produced a 3- to 4-fold expansion of gene-cor-
rected long term myelopoiesis in both treated patients, notably
without signs of leukaemia to date. Prospective monitoring of
vector integration sites in clinical gene therapy studies is feasible,
can detect possible side effects of gene therapy in real-time and
may gain new insights in basic monogenic mechanisms leading
to specific clonal behaviour in vivo.
doi:10.1016/j.ejcsup.2006.04.133
S58. TARGETING THE EGF RECEPTOR: EXPERIENCE AND
LESSONS
John Mendelsohn. The University of Texas M. D. Anderson Cancer
Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA.
E-mail address: jmendelsohn@mdanderson.org
In 1981 we hypothesized that blockade of the binding site for EGF
and TGF-alpha on EGFR with an antireceptor monoclonal anti-
body (mAb) might be an effective anti-cancer therapy, by inhibit-
ing activation of the receptor tyrosine kinase. Murine mAb 225
inhibited EGFR tyrosine kinase activity, and inhibited tumor cell
growth in cultures and in nude mouse xenografts. C225 (cetuxi-
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